A vaccine designed to prevent a painful skin infection may have an unexpected connection to the aging brain.
Older adults who received the shingles vaccine were 24% less likely to be diagnosed with dementia over the following four years than those who remained unvaccinated, according to a new study involving more than 500,000 people.
The finding does not establish that the vaccine prevents dementia. But the size of the analysis, combined with earlier research pointing in a similar direction, adds to growing interest in whether protection against shingles could have benefits that extend beyond the infection itself.
More Than 500,000 Older Adults Were Followed
Researchers from Brown University and collaborating institutions analyzed Medicare claims and electronic health records for 509,926 adults aged 66 and older who entered more than 5,500 skilled nursing facilities across the United States between 2017 and 2022.
The participants had no previous dementia diagnosis and were eligible for the recombinant shingles vaccine, Shingrix.
Of the people included, 8,843 received at least one dose of the vaccine. Researchers then compared their dementia diagnoses over four years with those of people who remained unvaccinated.
The difference was noticeable.
Dementia was diagnosed in 18.8% of vaccinated participants, compared with 24.6% of those who did not receive the vaccine. Researchers calculated that vaccination was associated with a 24% lower relative risk of dementia.
That works out to an absolute difference of roughly six percentage points between the groups.
But why would a vaccine against shingles have anything to do with dementia?
The Connection May Begin with the Virus Itself
Shingles occurs when the varicella-zoster virus, the virus that causes chickenpox, reactivates after remaining dormant in the body.
The virus can persist in nerve tissue for years. When it reactivates, it can cause the characteristic painful rash and, in some cases, complications affecting the nervous system.
That has led scientists to investigate whether preventing viral reactivation could somehow influence processes involved in brain aging.
One possibility is inflammation. Shingles can trigger inflammation involving the nervous system and has also been associated with an increased risk of stroke. Researchers are investigating whether preventing these effects could partly explain the lower dementia rates observed among vaccinated people.
But that remains a possible explanation, not an established mechanism.
The study itself cannot show what happened inside the brains of the vaccinated participants.
Researchers Tried to Make the Comparison More Reliable
There is an obvious problem when researchers compare people who choose to get vaccinated with people who do not.
The two groups may differ in ways unrelated to the vaccine.
People who receive recommended vaccinations may, for example, be more likely to seek medical care or follow other preventive-health advice. Researchers refer to this potential problem as healthy-user bias.
To make the comparison more rigorous, the researchers used a method called target trial emulation. It uses real-world health records to recreate some of the conditions that researchers would expect to see in a randomized clinical trial.
The analysis still cannot replace an actual randomized trial, but it allows scientists to examine questions that would be difficult to study prospectively in such a large population.
The researchers also adjusted their analysis for other factors that could influence dementia diagnoses.
The association remained after those adjustments.
That does not turn the finding into proof of cause and effect, but it makes the result harder to dismiss as a simple difference between the two groups.
Earlier Research Points in the Same Direction
The Brown study is not the first to uncover a possible relationship between shingles vaccination and dementia.
In February 2026, researchers reported in Nature Communications that receiving two doses of the recombinant zoster vaccine was associated with a 51% lower risk of dementia among adults aged 65 and older in a separate retrospective study. The researchers also found that the association remained after accounting for potential healthy-vaccinee bias.
Earlier research involving the older live shingles vaccine also found associations with a lower risk of dementia. A 2025 Nature study using a natural experiment in Wales found that receiving the zoster vaccine was associated with a 20% relative reduction in new dementia diagnoses over seven years.
The studies used different populations and research methods, so their percentages should not be directly compared.
What they do provide is a recurring signal: people who receive shingles vaccination appear to develop dementia less often than comparable unvaccinated groups.
The Vaccine Should Not Yet Be Considered a Dementia Treatment
That distinction is important.
The latest study was observational. Researchers looked at what happened to people who received the vaccine rather than randomly assigning participants to receive the vaccine or not.
As a result, the findings cannot prove that Shingrix itself prevented dementia.
It is also possible that factors the researchers could not fully measure contributed to the difference between the groups.
For that reason, scientists still need stronger evidence from carefully designed clinical trials before the vaccine can be considered specifically for dementia prevention.
There is also no recommendation to receive a shingles vaccine to prevent dementia.
The established reason for vaccination remains protection against shingles and its complications.
A Familiar Vaccine Is Raising an Unfamiliar Question
What makes the finding particularly interesting is that the potential connection does not involve an experimental drug designed for the brain.
It involves a vaccine already used to prevent a common infection in older adults.
That gives researchers an opportunity to investigate whether preventing a virus that can affect the nerves might also influence long-term brain health.
For now, the evidence does not support the claim that a shingles vaccine can prevent dementia. But across several studies, the same unexpected pattern is becoming harder to ignore.
The next challenge is determining whether the association reflects a genuine protective effect and, if it does, whether preventing shingles is actually protecting the brain or whether the vaccine is triggering another biological effect that scientists have yet to understand.
Until that question is answered, the shingles shot remains a vaccine against shingles, not a dementia treatment. But researchers now have a compelling reason to keep looking beyond its original purpose.
